[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yi Liang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":139},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,70,93,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100604695","evaluation-of-the-efficacy-of-electroacupuncture-in-the-treatment-of-chronic-atrophic-gastritis-100604695",false,"NCT07152860","Evaluation of the Efficacy of Electroacupuncture in the Treatment of Chronic Atrophic Gastritis","Evaluation of the Efficacy of Electroacupuncture in the Treatment of Chronic Atrophic Gastritis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Meets the diagnostic criteria for chronic atrophic gastritis (CAG) (at the time of enrolment, participants must provide reports from endoscopic and pathological examinations conducted within the past year prior to the study start date, both of which indicate chronic atrophic gastritis)\n* Age between 18 and 75 years old, no gender restrictions;\n* Has not received acupuncture treatment within the past month;\n* Not participated in any other ongoing studies within the past 2 months.\n* Understand and agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Autoimmune gastritis (type A chronic atrophic gastritis);\n* Participants with a positive C-13 urea breath test at baseline (Helicobacter pylori infection);\n* Patients diagnosed with high-grade intraepithelial neoplasia based on upper gastrointestinal endoscopy and gastric mucosal biopsy pathology;\n* Patients with confirmed or unresolved malignant tumours, particularly oesophageal cancer and gastric cancer; patients with other upper gastrointestinal lesions such as peptic ulcers or Barrett's oesophagus;\n* Patients with severe lesions in major organs (heart, liver, kidney, lung, etc.) or other autoimmune diseases (rheumatic diseases, Crohn's disease, autoimmune pancreatitis, etc.); Persons with cardiac pacemakers;\n* Pregnant and lactating women;\n* Patients with infectious diseases such as tuberculosis, hepatitis, or HIV\u002FAIDS;\n* Individuals with a history of alcohol abuse, drug use, or illicit drug use;\n* Individuals who have used other prokinetic agents, mucosal protectants, acid-suppressing medications, or related traditional Chinese medicines within the past two weeks;\n* Individuals currently participating in or who have participated in other clinical trials within the past two months; individuals unable to tolerate acupuncture or with contraindications for acupuncture treatment; and individuals deemed unsuitable for participation in this clinical trial by the research team.","ALL","18 Years","75 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Brief Summary Template for the Study:\n\nThis clinical trial aims to evaluate whether electroacupuncture can treat chronic atrophic gastritis (CAG) in adult subjects aged 18 to 75 years (including both males and females), all of whom have been diagnosed with CAG based on endoscopic and histopathological criteria. The primary objectives of this study are to answer the following questions:\n\n* Can 5 Hz electroacupuncture therapy reverse the pathological state of the gastric mucosa in patients with chronic atrophic gastritis?\n* Can 5 Hz electroacupuncture therapy improve gastrointestinal symptoms in patients with chronic atrophic gastritis?\n* Is there a difference in efficacy between the combination of 5 Hz electroacupuncture therapy and gastric mucosa protectants versus the use of gastric mucosa protectants alone in the treatment of chronic atrophic gastritis?\n\nResearchers will compare the effects of 5 Hz electroacupuncture combined with gastric mucosal protectants versus gastric mucosal protectants alone to determine which method can reverse the pathological state of gastric mucosa and provide more significant symptom relief.\n\nParticipants will:\n\n* Receive acupuncture treatment at specific acupoints (such as Shangwan(CV13), Zhongwan (CV12) ,Xiawan(CV10), Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39).) Electroacupuncture is administered at the abdominal points 'CV13-CV12' and 'ST21-ST21', alongside bilateral lower limb points 'ST36-ST39', using an SDZ-IIB handheld electroacupuncture device (Huatuo brand, Suzhou Medical Supplies Factory Co., Ltd.). Receive electroacupuncture treatment at 5Hz.for 30-minute sessions, three times weekly for 1-8 weeks; twice weekly from weeks 9 to 16, once weekly from weeks 17 to 24, for a total of 24 weeks, comprising 48 treatment sessions.\n* Be randomly assigned to one of the following groups: 5 Hz electroacupuncture combined with gastric mucosal protective agent group or gastric mucosal protective agent group (control group).\n* Have their dyspepsia symptoms, quality of life, and any adverse reactions continuously monitored and assessed throughout the study period.",[27],"Chronic Atrophic Gastritis",[29,30],"Chronic atrophic gastritis","electroacupuncture","NOT_YET_RECRUITING","2025-12-15",{"date":34,"type":35},"2025-12-19","ACTUAL",{"date":37,"type":21},"2025-12-30",{"date":39,"type":21},"2026-12-30",{"name":41,"class":42},"Yi Liang","OTHER",3,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100563649","evaluation-of-the-efficacy-of-electroacupuncture-in-the-treatment-of-functional-dyspepsia-100563649","NCT06618911","Evaluation of the Efficacy of Electroacupuncture in the Treatment of Functional Dyspepsia","Evaluation of the Efficacy of Electroacupuncture in the Treatment of Functional Dyspepsia: A Pilot Study","Inclusion Criteria:\n\n* Diagnosed with functional dyspepsia based on Rome IV diagnostic criteria.\n* Aged 18 to 80 years, inclusive, with no gender restrictions.\n* Normal endoscopy results within the past year, showing no structural explanation for symptoms.\n* No acupuncture treatment in the last month.\n* Not participating in any other clinical trials in the past 2 months.\n* Able to understand and provide informed consent.\n\nExclusion Criteria:\n\n* Presence of serious or malignant diseases (e.g., cirrhosis, heart failure, gastrointestinal tumors) that could explain dyspepsia symptoms.\n* Positive for Helicobacter pylori infection based on C-13 urea breath test or gastric biopsy.\n* History of gastrointestinal surgery (excluding laparoscopic and other minimally invasive surgeries).\n* Recent use (within 2 weeks) of medications affecting dyspepsia, including prokinetics, proton pump inhibitors, antacids, or antidepressants.\n* Presence of severe mental or physical conditions, such as dementia or illiteracy, that could interfere with study participation.\n* Severe coagulation disorders.\n* Substance abuse or alcohol dependence.\n* Pregnant or breastfeeding women.","80 Years",{"count":53,"type":21},180,[24],"Brief Summary Template for the Study:\n\nThe goal of this clinical trial is to evaluate whether electroacupuncture can treat functional dyspepsia (FD) in adult participants aged 18 to 65 years, including both males and females, who have been diagnosed with functional dyspepsia based on the Rome IV criteria. The main questions it aims to answer are:\n\n* Does 5 Hz electroacupuncture improve symptoms in functional dyspepsia patients?\n* Does 100 Hz electroacupuncture improve symptoms in functional dyspepsia patients?\n* Are there differences in the efficacy between 5 Hz and 100 Hz electroacupuncture in treating functional dyspepsia and its subtypes (PDS and EPS)?\n\nResearchers will compare the effects of 5 Hz electroacupuncture, 100 Hz electroacupuncture, and sham electroacupuncture to determine which approach provides more significant symptom relief and whether different frequencies have varying impacts on FD subtypes.\n\nParticipants will:\n\n* Receive electroacupuncture treatment at specific acupoints (such as Liangmen, Tianshu, Zusanli, and Xiajuxu) for 30-minute sessions, 3 times a week for 4 weeks.\n* Be randomly assigned to one of the following groups: 5 Hz electroacupuncture, 100 Hz electroacupuncture, or sham electroacupuncture (control).\n* Have their functional dyspepsia symptoms, quality of life, and any adverse effects monitored and evaluated throughout the study.",[57],"Functional Dyspepsia",[30,59],"functional dyspepsia","RECRUITING","2025-08-24",{"date":63,"type":35},"2025-08-29",{"date":65,"type":35},"2025-04-13",{"date":67,"type":21},"2026-09-30",{"name":41,"class":42},4,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100586192","association-of-sleep-quality-with-pathologic-staging-acupuncture-treatment-in-patients-with-chronic-atrophic-gastritis-a-cross-sectional-study-100586192","NCT06912178","Association of Sleep Quality With Pathologic Staging, Acupuncture Treatment in Patients With Chronic Atrophic Gastritis: a Cross-sectional Study","Inclusion Criteria:\n\n1. Have been diagnosed with chronic atrophic gastritis;\n2. Be between the ages of 18 and 75, with no restrictions on gender;\n3. Read the informed consent form, sign it, and consent to participate in this study.\n\nExclusion Criteria:\n\n1. autoimmune gastritis (chronic atrophic gastritis type A);\n2. patients with gastroesophageal reflux disease (GERD) as determined by endoscopy or other examinations, or patients with high-grade intraepithelial neoplasia pathologically as determined by upper gastrointestinal endoscopy and gastric mucosal biopsy;\n3. patients with confirmed or unexcluded malignant tumors, particularly esophageal and gastric cancer;patients with other upper gastrointestinal pathologies, such as Barrett's esophagus or peptic ulcer;\n4. additional physical, mental, psychological, or pathological conditions that may impact sleep scores, such as the use of medications for insomnia, night shifts, jet lag, major events, severe neurosis, menopausal syndrome, uncontrolled hyperthyroidism, severe diabetic peripheral neuropathy, within a month after surgical trauma, etc.\n5. People who use medicines that can make you sleepy at the same time and stop using them for less than a month;\n6. People who can't finish the questionnaire because they're unconscious, can't talk regularly, or have other issues; people who don't have enough information.",{"count":77,"type":21},120,"OBSERVATIONAL","In order to inform clinical treatment decisions and maximize treatment outcomes, this observational study set out to examine the relationship between pathological severity and sleep quality in patients with CAG. The idea that \"if the stomach is not in harmony, you will be restless\" is supported by this evidence from traditional Chinese medicine. Assessing patients' knowledge and acceptance of acupuncture therapy, determining the current general trend in CAG treatment, and assessing the initial effectiveness of acupuncture therapy in treating CAG with sleep disturbances. It is envisaged that the aforementioned investigations will aid in further refining the clinical research strategy of acupuncture and moxibustion with CAG with sleep disorders, enhance the effectiveness of treatment, and offer a more cost-effective and practical choice for treating CAG with sleep disorders.\n\nThe primary research issue is: can the traditional Chinese medical notion of \"restlessness due to disharmony of the stomach\" be validated in order to ascertain whether there is a correlation between pathological severity and sleep quality in patients with chronic atrophic gastritis? The pathological conditions of CAG patients were gathered based on the most recent gastroscopy report within a year, and the patients' sleep quality scores from the previous month were gathered via a questionnaire.",[81],"Chronic Atrophic Gastritis (CAG)",[83],"chronic atrophic gastritis; sleep quality; OLGA; OLGIM; pathologic; acupuncture; cross-sectional","2025-03-29",{"date":86,"type":35},"2025-04-04",{"date":88,"type":21},"2025-03-30",{"date":90,"type":21},"2026-03-30",{"name":41,"class":42},1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":114,"locationsCount":4},"100530554","the-effect-of-patient-controlled-teas-vs-sham-teas-for-improve-quality-of-life-in-patients-with-cancer-pain-100530554","NCT06188286","The Effect of Patient-Controlled TEAS vs Sham TEAS for Improve Quality of Life in Patients With Cancer Pain","Patient-Controlled Transcutaneous Acupoint Electrical Stimulation to Improve Quality of Life in Patients With Cancer Pain","Participants who had been diagnosed with cancer pain were eligible if they ①were 18 to 75 years old, ②had NRS pain score of ≥4 in the previous 1 week, or had regular use of analgesics, ③ anticipated survival of at least 6 months, ④ECOG-PS score ≤2 points, ⑤stable vital signs, clear consciousness, and the ability to correctly judge their pain, communication is unhindered, able to cooperate with researchers to complete relevant research assessments, ⑥voluntarily participate in this study and sign the informed consent form. Exclusion criteria included the following: ①Have venous thrombosis of the upper and lower limbs (below the elbow\u002Fknee joint), active cerebrovascular disease, severe cardiopulmonary dysfunction, or patient is clinically unstable (eg, acute infections, electrolyte disturbances).②Patients with pacemaker implantation or metal implantation in the body. ③People with local skin at acupoints lesions, poor skin conditions, or other people unsuitable for PC-TEAS treatment. ④Cancer patients who are planning to become pregnant recently or are pregnant. ⑤Have a psychiatric disorder or severe cognitive impairment who are unable to communicate. ⑥Participating in other clinical trials.",{"count":101,"type":21},94,[24],"The conduct of a pilot trial is of great significance as a means of assessing the feasibility and harmonization of the research and is a very necessary precursor to the better conduct of formal trials. The primary aim of this pilot study is to assess the feasibility of a PC-TEAS in improving the quality of life of cancer patients with pain, with the aspiration of providing process evidence base and an assessment of the intervention for conducting a formal trial. the secondary outcome is to assess the clinical efficacy of the PC-TEAS.",[105],"Cancer Pain",[107],"transcutaneous electrical nerve stimulation","2024-12-19",{"date":110,"type":35},"2024-12-24",{"date":112,"type":21},"2024-12-25",{"date":37,"type":21},{"name":41,"class":42},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":122,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":92},"100570473","correlation-among-various-olga-and-olgim-stages-digestive-symptom-scores-and-acupuncture-treatment-in-patients-with-chronic-atrophic-gastritis-100570473","NCT06707701","Correlation Among Various OLGA and OLGIM Stages, Digestive Symptom Scores, and Acupuncture Treatment in Patients with Chronic Atrophic Gastritis","Correlation Among Various OLGA and OLGIM Stages, Digestive Symptom Scores, and Acupuncture Treatment in Patients with Chronic Atrophic Gastritis:a Multicenter Cross-sectional Pilot Survey","Inclusion Criteria:\n\n* Fulfill the diagnostic criteria for chronic atrophic gastritis;\n* Individuals aged 18 to 75 years, irrespective of gender;\n* Capable of comprehending and consenting to participate in this study by signing the informed consent form.\n\nExclusion Criteria:\n\n* Autoimmune gastritis (type A chronic atrophic gastritis);\n* Patients diagnosed with Gastroesophageal Reflux Disease (GERD) by endoscopy or other examinations or patients diagnosed with high-grade intraepithelial neoplasia by upper gastrointestinal endoscopy and gastric mucosal biopsy pathology;\n* Patients with confirmed or unable to exclude malignant tumors, especially esophageal and gastric cancers; patients with other upper gastrointestinal tract pathologies such as peptic ulcer or Barrett's esophagus;\n* Those who cannot complete the questionnaire due to unconsciousness, inability to communicate normally or other reasons; those with incomplete information.",{"count":123,"type":21},400,"Brief Summary Template for the Study:\n\nThe goal of this observational study is to examine the relationship between digestive symptom scores, serum pepsinogen indices, and histopathological OLGA and OLGIM systematic staging of the gastric mucosa in patients with chronic atrophic gastritis(CAG), aiming to determine the degree of correlation between clinical manifestations, non-invasive laboratory tests, and the gold standard of diagnostic histopathology.To evaluate the comprehensive therapy, readiness and acceptance of acupuncture, utilization rates of various acupuncture therapies, self-assessed efficacy of acupuncture, and endoscopic histopathological alterations in patients with CAG.According to the aforementioned study, it is anticipated to enhance the optimization of acupuncture clinical research protocols for chronic atrophic gastritis, improve treatment efficacy, and offer more effective and rational therapy alternatives for patients.The main question it aims to answer is:\n\nTo determine if the outcomes of combined serologic testing of symptoms in patients with CAG can serve as a method for monitoring disease development and if long-term follow-up can be supported？\n\nA group of participants with recorded GI symptom scores and blood pepsinogen levels will respond to online survey questions regarding the severity of their chronic atrophic gastritis progression over the course of 1 year.",[81],[127,128,129,130,131],"chronic atrophic gastritis","global overall symptom scale","serum pepsinogen","operative link for gastritis assessment","operative link for gastric intestinal metaplasia assessment","2024-11-27",{"date":134,"type":35},"2024-12-02",{"date":136,"type":21},"2024-12-30",{"date":37,"type":21},{"name":41,"class":42},""]